Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osalmid in Multiple Myeloma
NCT03670173Phase 2Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Oct 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Osalmid in multiple myeloma (MM), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Overall Response Rate at 16 weeks. Status: unknown.
02
Drugs
Osalmid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03670173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670173.